Journal of Microwave Surgery
Online ISSN : 1882-210X
Print ISSN : 0917-7728
ISSN-L : 0917-7728
Original Article
  • 別府 透, 山下 信吾, 山本 雅一, 吉田 雅博, 馬場 秀夫, 高田 忠敬
    2020 年 37 巻 5 号 p. 1-6
    発行日: 2020年
    公開日: 2020/08/09
    ジャーナル フリー
    Microwave coagulation therapy (MCT) for liver tumors had initially developed in Japan and now is spreading worldwide. Microwave thermosphere ablation is a new concept using cooling antenna to create a larger spherical necrotic area. Recently, the indications of MCT is spreading from hepatocellular carcinoma to liver metastases. MCT is recommended only for patients with unresectable colorectal liver metastases (CRLM); ≤ 3cm and ≤ 3 nodules in combination with systemic chemotherapy. MCT has some benefits compared with radiofrequency ablation: 1) Shorter ablation time; 2) Lower local recurrence rate; 3) better disease-free and overall survival; 4) Complete necrosis even for the tumor adjacent to the large vessels; and 5) Similar complication rates. In summary, MCT is evolving as one of the promising local treatments for liver metastases; however, a randomized control trial is required to create solid evidences.